Figures & data
Table 1 Baseline Patient Demographic And Clinical Characteristics (n=94)
Table 2 Clinical Activity Summary Of Osimertinib
Table 3 Cox Regression For PFS
Figure 1 Progression-free Survival (PFS) in the overall population (A), in patients with or without detectable T790M mutation (B), in patients of T790M co-occurring with exon19 deletion or L858R mutation (C), in patients with T790M detected of tumor samples or plasma ctDNA samples (D). Tick marks indicate censored observations. Abbreviations: CI, confidence interval; HR, hazard ratio.
Table 4 Osimertinib Activity In T790M-Positive Patients With Co-Occurring Mutation
Table 5 Adverse Events (n=94)